The US Association for Accessible Medicines hires for three key leadership roles, while Australia’s Generic and Biosimilar Medicines Association has named Fresenius Kabi’s director in Australia as its newest board member. Coherus’ vice president of market access and government affairs, Thomas Nusbickel, joins CorMedix as chief commercial officer, while other major firms make board changes.

Pfenex founder and chief business officer Patrick Lucy has left the company to join Lykan Bioscience. Meanwhile, Samsung Biologics has announced the appointment of a new president and CEO, as the Australian generics and biosimilars association appoints a new chair.

Among the antibiotics that have garnered a qualified infectious disease product designation, a collection of late-stage products are targeted at local delivery, especially inhaled and vaginal formulations.

Biscayne and Japanese CRO SNBL create spin-outs to advance programs; liver disease specialist Ascletis gains funds as it shifts away from HCV; Neon gets $100m to put into its cancer vaccines; and other highlights of recent VC funding.